Status:
RECRUITING
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
Lead Sponsor:
Chongqing Medical University
Conditions:
Metabolic Dysfunction-associated Fatty Liver Disease
Hepatic Steatosis
Eligibility:
All Genders
18-90 years
Brief Summary
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of ...
Detailed Description
Background Inflammation is related to the occurrence and development of fatty liver. Our research aimed to investigate the link between an inflammatory indicator, high-sensitivity C-reactive protein t...
Eligibility Criteria
Inclusion
- Total participants from NHANES 2017-2020
- Participants diagnosed with MAFLD. Metabolic dysfunction-associated fatty liver disease (MAFLD) is the term used to describe hepatic steatosis in the presence of metabolic abnormalities, excess weight, obesity, or type 2 diabetic mellitus.
- Diagnosis of diabetes mellitus: (1) taking glucose-lowering drugs; (2) HbA1c ≥ 6.5% (48 mmol/mol); (3) fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL); (4) 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L (200 mg/dL).
- Overweight or obesity: defined as BMI≥25 kg/m2 in Caucasians or BMI≥23 kg/m2 in Asians
- If presence of at least two metabolic risk abnormalities:
- Waist circumference≥102/88 cm in Caucasian men and women (or≥90/80 cm in Asian men and women)
- Blood pressure≥130/85 mmHg or specific drug treatment
- Plasma triglycerides≥150 mg/dl (≥1.70 mmol/L) or specific drug treatment
- Plasma HDL-cholesterol \<40 mg/dl (\<1.0 mmol/L) for men and \<50 mg/dl (\<1.3 mmol/L) for women or specific drug treatment
- Prediabetes (i.e., fasting glucose levels 100 to 125 mg/dl \[5.6 to 6.9 mmol/L\], or 2-hour post-load glucose levels 140 to 199 mg/dl \[7.8 to 11.0 mmol\] or HbA1c 5.7% to 6.4% \[39 to 47 mmol/mol\])
- Homeostasis model assessment of insulin resistance score≥2.5
- Plasma high-sensitivity C-reactive protein level \>2 mg/L
Exclusion
- Liver ultrasound data not available
- participants without complete clinical data
- participants under 18 years old
- participants with cancer.
Key Trial Info
Start Date :
July 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 28 2026
Estimated Enrollment :
7000 Patients enrolled
Trial Details
Trial ID
NCT05974904
Start Date
July 18 2023
End Date
December 28 2026
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400000